Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

496 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Initial genome sequencing and analysis of multiple myeloma.
Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, Bernstein BE, Drier Y, Fonseca R, Gabriel SB, Hofmeister CC, Jagannath S, Jakubowiak AJ, Krishnan A, Levy J, Liefeld T, Lonial S, Mahan S, Mfuko B, Monti S, Perkins LM, Onofrio R, Pugh TJ, Rajkumar SV, Ramos AH, Siegel DS, Sivachenko A, Stewart AK, Trudel S, Vij R, Voet D, Winckler W, Zimmerman T, Carpten J, Trent J, Hahn WC, Garraway LA, Meyerson M, Lander ES, Getz G, Golub TR. Chapman MA, et al. Among authors: jagannath s. Nature. 2011 Mar 24;471(7339):467-72. doi: 10.1038/nature09837. Nature. 2011. PMID: 21430775 Free PMC article.
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Hideshima T, Xiao H, Esseltine D, Schenkein D, Anderson KC; SUMMIT Investigators. Richardson PG, et al. Among authors: jagannath s. Blood. 2005 Nov 1;106(9):2977-81. doi: 10.1182/blood-2005-02-0691. Epub 2005 Jul 14. Blood. 2005. PMID: 16020506 Free article. Clinical Trial.
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA. Richardson PG, et al. Among authors: jagannath s. J Clin Oncol. 2006 Jul 1;24(19):3113-20. doi: 10.1200/JCO.2005.04.7779. Epub 2006 Jun 5. J Clin Oncol. 2006. PMID: 16754936 Clinical Trial.
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
Jagannath S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Esseltine DL, Anderson KC. Jagannath S, et al. Br J Haematol. 2008 Nov;143(4):537-40. doi: 10.1111/j.1365-2141.2008.07359.x. Epub 2008 Sep 6. Br J Haematol. 2008. PMID: 18783399 Free article. Clinical Trial.
Conflicts of interest, authorship, and disclosures in industry-related scientific publications.
Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Melissa Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA. Fonseca R, et al. Among authors: jagannath s. Mayo Clin Proc. 2010 Feb;85(2):197-9; author reply 201-4. doi: 10.4065/mcp.2009.0559. Mayo Clin Proc. 2010. PMID: 20118399 Free PMC article. No abstract available.
The current status and future of multiple myeloma in the clinic.
Jagannath S, Kyle RA, Palumbo A, Siegel DS, Cunningham S, Berenson J. Jagannath S, et al. Clin Lymphoma Myeloma Leuk. 2010 Feb;10(1):28-43. doi: 10.3816/CLML.2010.n.003. Clin Lymphoma Myeloma Leuk. 2010. PMID: 20223727 Review.
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Kaster S, Delaney C, Hideshima T, Mitsiades CS, Knight R, Esseltine DL, Anderson KC. Richardson PG, et al. Among authors: jagannath s. Blood. 2010 Aug 5;116(5):679-86. doi: 10.1182/blood-2010-02-268862. Epub 2010 Apr 12. Blood. 2010. PMID: 20385792 Free PMC article. Clinical Trial.
The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group.
Terpos E, Dimopoulos MA, Sezer O, Roodman D, Abildgaard N, Vescio R, Tosi P, Garcia-Sanz R, Davies F, Chanan-Khan A, Palumbo A, Sonneveld P, Drake MT, Harousseau JL, Anderson KC, Durie BG; International Myeloma Working Group. Terpos E, et al. Leukemia. 2010 Oct;24(10):1700-12. doi: 10.1038/leu.2010.173. Epub 2010 Sep 2. Leukemia. 2010. PMID: 20811404 Free article. Review.
496 results